glp-1 analog fc fusion polypeptide and application thereof

A GLP-1 and fusion polypeptide technology, applied in the field of fusion proteins, can solve problems such as short half-life

Active Publication Date: 2021-05-14
SHENZHEN TAILI BIOTECHNOLOGY CO LTD
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] Based on this, the present invention provides a GLP-1 analogue Fc fusion polypeptide and its application to solve the problem of short biological half-life of traditional GLP-1 analogues

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • glp-1 analog fc fusion polypeptide and application thereof
  • glp-1 analog fc fusion polypeptide and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0016] In order to facilitate the understanding of the present invention, the present invention will be described more fully below with reference to the associated drawings. Preferred embodiments of the invention are shown in the accompanying drawings. However, the present invention can be embodied in many different forms and is not limited to the embodiments described herein. On the contrary, these embodiments are provided to make the understanding of the disclosure of the present invention more thorough and comprehensive.

[0017] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the technical field of the invention. The terms used herein in the description of the present invention are for the purpose of describing specific embodiments only, and are not intended to limit the present invention. As used herein, the term "and / or" includes any and all combinations of one or more of ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a GLP-1 analogue Fc fusion polypeptide and its application to solve the problem of short biological half-life of traditional GLP-1 analogues. The GLP-1 analogue in the GLP-1 analogue Fc fusion polypeptide has two site mutations relative to the wild-type GLP-1(7-37) sequence, wherein the alanine at position 8 is mutated into glycine, which can be To avoid enzymatic cleavage by dipeptidyl peptidase-IV (DPP-IV), the 22nd glycine is mutated to glutamic acid, which can enhance the biological activity of GLP-1; the human IgG2 Fc mutant mainly has three mutations, It reduces the ADCC and ADCP effects, and increases the affinity with FcRn, which is beneficial to prolong the half-life. It has been verified by experiments that the GLP-1 analogue Fc fusion polypeptide has high in vitro activity, and its biological half-life is significantly longer than that of current existing products. The GLP-1 analogue Fc fusion polypeptide can be applied in the research and development of drugs or health products for lowering blood sugar, treating diabetes, and slimming and weight loss.

Description

technical field [0001] The invention relates to the field of fusion proteins, in particular to a GLP-1 analogue Fc fusion polypeptide and its application. Background technique [0002] Glucagon-like peptide-1 (GLP-1) is a gastrointestinal polypeptide hormone, which is mainly secreted by three human tissues: L cells at the end of the intestine, alpha cells of the pancreas and central nervous system System (CNS). The effects of GLP-1 on blood glucose regulation mainly include: promoting insulin synthesis and secretion, delaying gastric emptying, inducing satiety, inhibiting glucagon secretion, and promoting pancreatic β-cell regeneration. GLP-1 is a safe hypoglycemic drug with no risk of hypoglycemia and significant weight loss. However, the half-life of natural GLP-1 is only 2-3 minutes, and it is easily degraded by dipeptidyl peptidase (DPP-IV), thus limiting the effectiveness of GLP-1 polypeptide as a drug for treating diabetes. Liraglutide, developed by Novo Nordisk, is...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C07K19/00A61K38/26A61P3/04A61P3/10
CPCA61K38/00A61P3/04A61P3/10C07K14/605
Inventor 兰万军王勇刚梁国龙龙婷李志坤林如新张桂涛陈静山
Owner SHENZHEN TAILI BIOTECHNOLOGY CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products